[Fluticasone propionate in the treatment of perennial allergic rhinitis: open multicenter trial].
One hundred and ten patients with perennial allergic rhinitis, currently symptomatic, were treated with fluticasone proprionate nasal spray (Flixonase) in open, multicentre efficacy and safety study. The drug studied statistically significantly decreased all symptoms of the disease conjunctivitis included, in the first week of treatment in the patient's and doctor's assessment. The full effect of treatment was revealed in the third week. There was significant protective effect observed during two weeks after the cessation of treatment. Adverse events were mild and occurred in fifteen cases, in two cases could be due to the drug (< 2%).
Kokot
M
M
Działu Medycznego, GlaxoWellcome Poland Ltd.
D000281:Administration, Intranasal; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone